11C-Choline PET/CT and PSA kinetics

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue SUPPL. 1, 2013, Pages

  Castellucci, Paolo ^a   Picchio, Maria ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

Author keywords

Choline; PET CT; Prostate cancer; PSA kinetics

Indexed keywords

CHOLINE C 11; CHOLINE F 18; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CARBON; CHOLINE; DIAGNOSTIC AGENT;

BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; KINETICS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; MALE; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; PROSTATE TUMOR;

CARBON RADIOISOTOPES; CHOLINE; HUMANS; MALE; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECURRENCE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84891555077     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2377-z     Document Type: Review

References (35)

1. Kataja VV, Bergh J. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann Oncol. 2005;16 Suppl 1:i34-6.
2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD et al. Guidelines on prostate cancer. Arnhem: European Association of Urology; 2012.
3. Naya Y, Okihara K, Evans RB, Babaian RJ. Efficacy of prostatic fossa biopsy in detecting local recurrence after radical prostatectomy. Urology. 2005;66:350-5.
4. Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol. 2008;179:906-10.
5. Cher ML, Bianco Jr FJ, Lam JS, Davis LP, Grignon DJ, Sakr WA, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol. 1998;160:387-91.
6. Gomez P, Manoharan M, Kim SS, Soloway MS. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int. 2004;94: 299-302.
7. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, DeKernion JB, et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol. 2004;171(6 Pt 1):2260-4.
8. Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med. 2008;49:2031-41.
9. 11C-choline PET/CT with histopathologic step-section analysis. J Nucl Med. 2005;46:1642-9.
10. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol. 2008;54:392-401.
11. Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of [11C]Choline-positron emission tomography for restaging prostate cancer: a comparison with [18F]fluorodeoxyglucosepositron emission tomography. J Urol. 2003;169:1337-40.
12. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [(11)C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18-23.
13. Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [11C]Choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:301-9.
14. 11C-Choline PET/ CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50(9):1394-400.
15. Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, et al. PSA doubling time for prediction of 11C Choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:1106-16.
16. 11C-Choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging. 2011; 38: 55-63
17. Breeuwsma AJ, Rybalov M, Leliveld AM, Pruim J, de Jong IJ. Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy. Q J Nucl Med Mol Imaging. 2012;56:440-6.
18. 11C-Choline positron emission tomography in recurrent prostate cancer. World J Urol. 2012. doI:10.1007/s00345-012-0908-z.
19. 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2012;39:589-96.
20. Graute V, Jansen N, Ubleis C, Seitz M, Hartenbach M, Scherr MK, et al. Relationship between PSA kinetics and [18F]fluoro-choline PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging. 2012;39:271-82.
21. National Collaborating Centre for Cancer. Managing relapse after radical treatment. In Prostate cancer: diagnosis and treatment. Chap 5. Cardiff: National Collaborating Centre for Cancer; 2008. p. 42-8. Available from: http://www.ncbi.nlm.nih.gov/books/NBK49517/.)
22. Scattoni V, Roscigno M, Raber M, Montorsi F, Da Pozzo L, Guazzoni G, et al. Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol. 2003;44:407-14.
23. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, et al. The role of positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011;59:51-60.
24. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376-83.
25. Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JM. Overall survival after prostate-specific-antigendetected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2000;48:629-33.
26. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-9.
27. Ratib O. PET/MRI: a new era in multimodality molecular imaging. Clin Transl Imaging. 2013. doi:10.1007/s40336-013-0003-5
28. 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2012;39:936-43.
29. Picchio M, Giovannini E, Crivellaro C, Gianolli L, di Muzio N, Messa C. Clinical evidence on PET/CT for radiation therapy planning in prostate cancer. Radiother Oncol. 2010;96:347-50.
30. Cochet A, Rousseau C, Dewas S, Supiot S, Brunotte F, Truc G. FluoroCholine(18F) (FCH) PET/CT for guiding image-guided salvage intensity-modulated radiation therapy (IG-sIMRT) in occult recurrence of prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2010;37 Suppl 2:OP336.
31. 11C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol. 2011;99:193-200.
32. Petersen C,Wahl A, Dahle J, Kretschmer M. [18F]fluoroethylcholine- PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol. 2011;6:44.
33. Di Muzio N, Fodor A, Berardi G, Mapelli P, Gianolli L, Messa C, et al. Lymph nodal metastases: diagnosis and treatment. Q J Nucl Med Mol Imaging. 2012;56:421-9.
34. Rigatti P, Suardi N, Briganti A, Da Pozzo LF, et al. Pelvic/ retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/ computed tomography. Eur Urol. 2011;60(5):935-43. doi:10.1016/ j.eururo.2011.07.060.
35. Pace L, Nicolai E, Aiello M, Catalano OA, Salvatore M. Whole Body PET/MRI in oncology: current status and clinical application. Clin Transl Imaging. 2013; in press